These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22661948)

  • 81. Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort.
    Gryn SE; Teft WA; Kim RB
    Pharmacogenet Genomics; 2014 Jul; 24(7):367-9. PubMed ID: 24915025
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro.
    Weissenstein U; Kunz M; Oufir M; Wang JT; Hamburger M; Urech K; Regueiro U; Baumgartner S
    BMC Complement Altern Med; 2019 Jan; 19(1):23. PubMed ID: 30658716
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen.
    Sanchez-Spitman AB; Moes DA; Gelderblom H; Dezentjé VO; Swen JJ; Guchelaar HJ
    Pharmacogenomics; 2017 Aug; 18(12):1125-1132. PubMed ID: 28745555
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
    Brauch H; Jordan VC
    Eur J Cancer; 2009 Sep; 45(13):2274-83. PubMed ID: 19592233
    [TBL] [Abstract][Full Text] [Related]  

  • 85. CYP2D6 and tamoxifen: DNA matters in breast cancer.
    Hoskins JM; Carey LA; McLeod HL
    Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects.
    Ahmad A; Shahabuddin S; Sheikh S; Kale P; Krishnappa M; Rane RC; Ahmad I
    Clin Pharmacol Ther; 2010 Dec; 88(6):814-7. PubMed ID: 20981001
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients.
    Areepium N; Panomvana D; Rungwanonchai P; Sathaporn S; Voravud N
    Breast Cancer (Dove Med Press); 2013; 5():73-8. PubMed ID: 24648760
    [TBL] [Abstract][Full Text] [Related]  

  • 88. CYP2D6 polymorphisms and the impact on tamoxifen therapy.
    Beverage JN; Sissung TM; Sion AM; Danesi R; Figg WD
    J Pharm Sci; 2007 Sep; 96(9):2224-31. PubMed ID: 17518364
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.
    Lammers LA; Mathijssen RH; van Gelder T; Bijl MJ; de Graan AJ; Seynaeve C; van Fessem MA; Berns EM; Vulto AG; van Schaik RH
    Br J Cancer; 2010 Sep; 103(6):765-71. PubMed ID: 20700120
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen.
    Sanchez-Spitman AB; Swen JJ; Dezentje VO; Moes DJAR; Gelderblom H; Guchelaar HJ
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):523-536. PubMed ID: 31008668
    [No Abstract]   [Full Text] [Related]  

  • 91. Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment.
    Buck SAJ; Braal CL; Hofman MM; Oomen-de Hoop E; de Bruijn P; Ghobadi Moghaddam-Helmantel IM; Hussaarts KGAM; Vastbinder MB; van Rossum-Schornagel QC; van Schaik RHN; Jager A; Koolen SLW; Mathijssen RHJ
    Ther Adv Med Oncol; 2022; 14():17588359221081075. PubMed ID: 35321309
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies.
    Reid JM; Goetz MP; Buhrow SA; Walden C; Safgren SL; Kuffel MJ; Reinicke KE; Suman V; Haluska P; Hou X; Ames MM
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1271-8. PubMed ID: 25318936
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen.
    Markopoulos C; Kykalos S; Mantas D
    World J Clin Oncol; 2014 Aug; 5(3):374-81. PubMed ID: 25114852
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients.
    Sanchez-Spitman AB; Böhringer S; Dezentjé VO; Gelderblom H; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2024 Jul; 116(1):155-164. PubMed ID: 38501904
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone.
    Rüdesheim S; Selzer D; Mürdter T; Igel S; Kerb R; Schwab M; Lehr T
    Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015360
    [TBL] [Abstract][Full Text] [Related]  

  • 96. CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer.
    Love RR; Desta Z; Flockhart D; Skaar T; Ogburn ET; Ramamoorthy A; Uy GB; Laudico AV; Van Dinh N; Quang le H; Van To T; Young GS; Hade E; Jarjoura D
    Springerplus; 2013 Dec; 2(1):52. PubMed ID: 23476897
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Endoxifen Concentration is Associated with Recurrence-Free Survival in Hormone-Sensitive Breast Cancer Patients.
    Lee B; Nam SJ; Kim SW; Yu J; Chae BJ; Lee SK; Ryu JM; Lee JE; Lee SY
    Cancer Res Treat; 2024 Jun; ():. PubMed ID: 38901825
    [TBL] [Abstract][Full Text] [Related]  

  • 98.
    Shimizu M; Uehara S; Ohyama K; Nishimura H; Tanaka Y; Saito Y; Suemizu H; Yoshida S; Yamazaki H
    Drug Metab Dispos; 2023 Oct; ():. PubMed ID: 37879849
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan.
    Grzegorzewski J; Brandhorst J; König M
    Front Pharmacol; 2022; 13():1029073. PubMed ID: 36353484
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Physiologically based pharmacokinetic modeling to predict the pharmacokinetics of codeine in different CYP2D6 phenotypes.
    Yang Y; Zhang X; Wang Y; Xi H; Xu M; Zheng L
    Front Pharmacol; 2024; 15():1342515. PubMed ID: 38756374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.